サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1414045

β遮断薬の世界市場レポート 2024年

Beta Blockers Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
β遮断薬の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

β遮断薬市場規模は近年力強く成長しています。2023年の91億6,000万米ドルから2024年には97億8,000万米ドルへと、CAGR6.8％で拡大します。過去の期間中、主に高血圧の管理、心血管系の病気の治療、心筋梗塞後のケア、片頭痛の予防措置、不安や震えの効果的な管理などの進歩に起因して拡大しました。

β遮断薬市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR5.9％で122億8,000万米ドルに成長します。今後予測される成長には、心血管疾患の有病率の増加、心不全治療における幅広い利用、併用療法の出現、高血圧ガイドラインの集中的な重視、新たな潜在的用途の探求が関係しています。この期間に予想される主な動向には、不安やパフォーマンスに関連するシナリオにおけるこれらの薬剤の利用、これらの薬剤が提供する潜在的な神経保護効果、個別化治療アプローチの採用、ジェネリック医薬品が市場に参入する影響、およびデジタルヘルスプラットフォームとの統合が含まれます。

心血管疾患の増加は、β遮断薬市場の拡大を促進すると予想されます。心血管疾患（CVD）には、心臓や血管に影響を及ぼすさまざまな疾患が含まれます。この急増は主に、不健康な食生活、座りがちなライフスタイル、運動不足、タバコの消費、肥満に起因しています。β遮断薬は、心臓や血管に有益な効果を発揮することにより、心血管系疾患の減少に大きく貢献します。その結果、心血管疾患の有病率の上昇は、β遮断薬市場の成長に大きく貢献しています。例えば、オーストラリア統計局の国民健康調査2020-21によると、2020-21年には18歳以上のオーストラリア人（成人人口の2.9％を占める）の推定57万1,000人が冠動脈性心疾患（CHD）と共に生活しています。

緑内障の有病率の高まりは、β遮断薬市場の拡大を後押しします。緑内障は、視覚情報を脳に伝達する視神経を損傷することにより、視力障害や失明の可能性につながる眼疾患群です。β遮断薬は眼圧（IOP）を下げることにより、緑内障の管理に極めて重要な役割を果たしています。そのメカニズムは、眼内液である房水の産生を減少させ、眼圧を緩和することにあります。例えば、ブライトフォーカス財団が2022年10月に報告したように、300万人以上のアメリカ人が緑内障に罹患しており、40歳以上の270万人が最も有病率の高い開放隅角緑内障に罹患しています。世界全体では8000万人が緑内障に罹患しており、この数字は2040年までに1億1100万人を超えると予想されています。

2023年のβ遮断薬市場で最大の地域は北米でした。アジア太平洋は、予測期間中、世界のβ遮断薬市場レポートにおいて最も急成長する地域となる見込みです。β遮断薬市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界のβ遮断薬市場促進要因と制約
    • 市場の促進要因
    • 市場の抑制要因
  • 世界のβ遮断薬の市場規模実績と成長、2018年から2023年
  • 世界のβ遮断薬市場規模と成長予測、2023年から2028年、2033年

第6章 市場セグメンテーション

  • 世界のβ遮断薬市場、タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 非選択的薬剤
  • 選択的エージェント
  • 世界のβ遮断薬市場、適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 狭心症
  • 心不全
  • 高血圧
  • その他の適応症
  • 世界のβ遮断薬市場、薬物別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • ベタキソロール
  • アセブトロール
  • エスモロール
  • その他の薬物
  • 世界のβ遮断薬市場、流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界のβ遮断薬市場、用途別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 心臓病
  • 高血圧
  • 緑内障
  • その他の用途

第7章 地域および国の分析

  • 世界のβ遮断薬市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界のβ遮断薬市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • β遮断薬市場の競合情勢
  • β遮断薬市場の企業プロファイル
    • Pfizer Inc.
    • Novartis AG
    • Merck &Co. Inc.
    • AstraZeneca plc
    • Johnson and Johnson

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

目次
Product Code: r11555

“Beta Blockers Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on beta blockers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for beta blockers? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The beta blockers market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type: Non-selective Agents; Selective Agents
  • 2) By Indication: Angina Pectoris; Heart Failure; High Blood Pressure; Other Indications
  • 3) By Drugs: Betaxolol; Acebutolol; Esmolol; Other Drugs
  • 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
  • 5) By Application: Cardiac Diseases; Hypertension; Glaucoma; Other Applications
  • Companies Mentioned: Pfizer Inc.; Novartis AG; Merck & Co. Inc.; AstraZeneca plc; Johnson and Johnson
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Beta blockers, also recognized as beta-adrenergic blocking agents, constitute a medication class widely employed in managing diverse cardiovascular conditions by mitigating heart activity. Their common prescription aims at regulating blood pressure, addressing angina, managing heart failure, and addressing certain cardiac rhythm irregularities.

Within the beta blockers spectrum, two primary types include non-selective agents and selective agents. Non-selective agents within the beta-blockers market encompass medications that impede or obstruct beta-adrenergic receptors' effects without a specific affinity toward any particular subtype. These agents serve to regulate various physiological functions encompassing heart rate, blood pressure, bronchial smooth muscle tone, and peripheral vascular resistance. Their use spans across conditions such as angina pectoris, heart failure, high blood pressure, and other ailments, often managed through medications such as betaxolol, acebutolol, esmolol, among others. These drugs are available through hospital pharmacies, retail outlets, and online platforms, catering to the treatment of cardiac diseases, hypertension, glaucoma, and related conditions.

The beta blockers market research report is one of a series of new reports from The Business Research Company that provides beta blockers market statistics, including beta blockers industry global market size, regional shares, competitors with a beta blockers market share, detailed beta blockers market segments, market trends, and opportunities, and any further data you may need to thrive in the beta blockers industry. This beta blockers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The beta blockers market size has grown strongly in recent years. It will grow from $9.16 billion in 2023 to $9.78 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. During the historical period, the expansion primarily stemmed from advancements in managing hypertension, treating cardiovascular ailments, post-myocardial infarction care, prophylactic measures for migraines, and the effective management of anxiety and tremors.

The beta blockers market size is expected to see strong growth in the next few years. It will grow to $12.28 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The projected growth in the upcoming period is linked to the increased prevalence of cardiovascular diseases, wider utilization in heart failure treatments, the emergence of combination therapies, a concentrated emphasis on hypertension guidelines, and the exploration of new potential applications. Key trends anticipated in this period encompass the utilization of these medications in anxiety and performance-related scenarios, the potential neuroprotective effects they offer, the adoption of individualized treatment approaches, the influence of generic versions entering the market, and their integration with digital health platforms.

The escalation in cardiovascular disease incidents is anticipated to propel the beta blockers market's expansion. Cardiovascular diseases (CVDs) encompass various disorders affecting the heart and blood vessels. This surge primarily results from unhealthy diets, sedentary lifestyles, insufficient exercise, tobacco consumption, and obesity. Beta blockers offer substantial aid in reducing cardiovascular cases by exerting beneficial effects on the heart and blood vessels. Consequently, the rising prevalence of cardiovascular diseases significantly contributes to the growth of the beta blockers market. For instance, as per the Australian Bureau of Statistics' National Health Survey 2020-21, an estimated 571,000 Australians aged 18 and above (constituting 2.9% of the adult population) were living with coronary heart disease (CHD) in 2020-21.

The mounting prevalence of glaucoma is poised to drive the beta blockers market's expansion. Glaucoma comprises a group of eye conditions leading to vision impairment and potential blindness by harming the optic nerve responsible for transmitting visual information to the brain. Beta blockers play a pivotal role in managing glaucoma by reducing intraocular pressure (IOP). Their mechanism involves diminishing the production of aqueous humor, the eye's internal fluid, thereby alleviating the pressure within the eye. For instance, as reported by the BrightFocus Foundation in October 2022, over three million Americans are affected by glaucoma, with 2.7 million individuals aged 40 and older experiencing its most prevalent form, open-angle glaucoma. Globally, 80 million people are afflicted by glaucoma, a figure anticipated to surpass 111 million by 2040.

Product innovation emerges as a prominent trend gaining traction within the beta blockers market. Key market players are directing efforts toward creating innovative products to fortify their market positioning. Notably, in January 2021, Merck obtained U.S. Food and Drug Administration (FDA) approval for VERQUVO (vericiguat), a medication designed to treat heart failure with reduced ejection fraction (HFrEF) in adults. This drug facilitates blood vessel relaxation, reduces cardiac strain, and enhances cardiac function, signifying a notable innovation within the market.

Leading companies in the beta blockers sector are prioritizing the introduction of advanced beta blocking agents for severe hypertension management and blood pressure reduction, aiming to gain a competitive advantage. Beta blockers play a crucial role in addressing severe hypertension and lowering blood pressure by blocking peripheral arteriolar alpha-adrenoceptors, thus reducing peripheral resistance and safeguarding the heart from reflex sympathetic drive. For instance, in March 2023, Hikma Pharmaceuticals PLC launched Labetalol Hydrochloride (Labetalol HCl) Injection, USP, in prefilled syringe (PFS) form in the US for treating severe hypertension and reducing blood pressure. Labetalol combines selective alpha1-adrenergic blocking and nonselective beta-adrenergic blocking activities in a single substance, functioning primarily by blocking peripheral arteriolar alpha-adrenoceptors to decrease resistance and lower blood pressure.

In November 2021, Merck, a German pharmaceutical company, completed the acquisition of Acceleron Pharma Inc. The undisclosed transaction provided Merck access to a comprehensive range of potential therapies targeting multiple disease sectors, particularly cardiovascular diseases and hypertension. Acceleron Pharma Inc., a US-based biopharmaceutical firm, specializes in harnessing the capabilities of the transforming growth factor (TGF)-beta protein superfamily to innovate treatments for cardiovascular and various other diseases.

Major companies operating in the beta blockers market report are Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca plc, Johnson and Johnson, Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Abbott Laboratories, Eagle Pharmaceuticals Inc., Neon Healthcare Ltd., Midas Pharma GmbH, Global Calcium PVT. LTD., AbbVie Inc., Mylan N.V., Boehringer Ingelheim International GmbH, Aspen Pharmacare Holdings Limited, Lupin Limited, Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Sandoz International GmbH, Wockhardt Ltd., Endo Pharmaceuticals Inc., Apotex Inc.

North America was the largest region in the beta blockers market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global beta-blockers market report during the forecast period. The regions covered in the beta blockers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the beta blockers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The beta blockers market consists of sales of sales of metoprolol, nebivolol, timolol, and labetalol. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Beta Blockers Market Characteristics

3. Beta Blockers Market Trends And Strategies

4. Beta Blockers Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Beta Blockers Market Size and Growth

  • 5.1. Global Beta Blockers Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Beta Blockers Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Beta Blockers Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Beta Blockers Market Segmentation

  • 6.1. Global Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Non-selective Agents
  • Selective Agents
  • 6.2. Global Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Angina Pectoris
  • Heart Failure
  • High Blood Pressure
  • Other Indications
  • 6.3. Global Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Betaxolol
  • Acebutolol
  • Esmolol
  • Other Drugs
  • 6.4. Global Beta Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • 6.5. Global Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Cardiac Diseases
  • Hypertension
  • Glaucoma
  • Other Applications

7. Beta Blockers Market Regional And Country Analysis

  • 7.1. Global Beta Blockers Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Beta Blockers Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Beta Blockers Market

  • 8.1. Asia-Pacific Beta Blockers Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Beta Blockers Market

  • 9.1. China Beta Blockers Market Overview
  • 9.2. China Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Beta Blockers Market

  • 10.1. India Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Beta Blockers Market

  • 11.1. Japan Beta Blockers Market Overview
  • 11.2. Japan Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Beta Blockers Market

  • 12.1. Australia Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Beta Blockers Market

  • 13.1. Indonesia Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Beta Blockers Market

  • 14.1. South Korea Beta Blockers Market Overview
  • 14.2. South Korea Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Beta Blockers Market

  • 15.1. Western Europe Beta Blockers Market Overview
  • 15.2. Western Europe Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Beta Blockers Market

  • 16.1. UK Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Beta Blockers Market

  • 17.1. Germany Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Beta Blockers Market

  • 18.1. France Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Beta Blockers Market

  • 19.1. Italy Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Beta Blockers Market

  • 20.1. Spain Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Beta Blockers Market

  • 21.1. Eastern Europe Beta Blockers Market Overview
  • 21.2. Eastern Europe Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Beta Blockers Market

  • 22.1. Russia Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Beta Blockers Market

  • 23.1. North America Beta Blockers Market Overview
  • 23.2. North America Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Beta Blockers Market

  • 24.1. USA Beta Blockers Market Overview
  • 24.2. USA Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Beta Blockers Market

  • 25.1. Canada Beta Blockers Market Overview
  • 25.2. Canada Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Beta Blockers Market

  • 26.1. South America Beta Blockers Market Overview
  • 26.2. South America Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Beta Blockers Market

  • 27.1. Brazil Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Beta Blockers Market

  • 28.1. Middle East Beta Blockers Market Overview
  • 28.2. Middle East Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Beta Blockers Market

  • 29.1. Africa Beta Blockers Market Overview
  • 29.2. Africa Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Beta Blockers Market Competitive Landscape And Company Profiles

  • 30.1. Beta Blockers Market Competitive Landscape
  • 30.2. Beta Blockers Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Novartis AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co. Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AstraZeneca plc
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Johnson and Johnson
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Beta Blockers Market Competitive Benchmarking

32. Global Beta Blockers Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Beta Blockers Market

34. Beta Blockers Market Future Outlook and Potential Analysis

  • 34.1 Beta Blockers Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Beta Blockers Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Beta Blockers Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer